Novel end points for clinical trials in young children with cystic fibrosis
Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality. While new CF disease-modifying agents are currently undergoing clinical trial evaluation, the implementation of such trials in young children is limited by the lack of age-appropri...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Expert Reviews Ltd
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/54974 |